Mesenchymal stem cell in vitro labeling by hybrid fluorescent magnetic polymeric particles for application in cell tracking

Supokawej, Aungkura; Nimsanor, Natakarn; Sanvoranart, Tanwarat; Kaewsaneha, Chariya; Hongeng, Suradej; Tangboriboonrat, Pramuan; Jangpatarapongsa, Kulachart

doi:10.1007/s00795-015-0102-7

Cited by 7 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A central question for MSC-based therapies is: where do cells go after their transplantation? One of the limiting factors of MSC transplantation is their interaction with the microenvironment ( 109 ). Therefore, it is essential to provide information about stem cells homing, motility, migration, and allocation ( 110 ).…”

Section: Msc Tracking and Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

et al. 2018

View full text Add to dashboard Cite

Within the last years, the use of stem cells (embryonic, induced pluripotent stem cells, or hematopoietic stem cells), Progenitor cells (e.g., endothelial progenitor cells), and most intensely mesenchymal stromal cells (MSC) has emerged as a promising cell-based therapy for several diseases including nephropathy. For patients with end-stage renal disease (ESRD), dialysis or finally organ transplantation are the only therapeutic modalities available. Since ESRD is associated with a high healthcare expenditure, MSC therapy represents an innovative approach. In a variety of preclinical and clinical studies, MSC have shown to exert renoprotective properties, mediated mainly by paracrine effects, immunomodulation, regulation of inflammation, secretion of several trophic factors, and possibly differentiation to renal precursors. However, studies are highly diverse; thus, knowledge is still limited regarding the exact mode of action, source of MSC in comparison to other stem cell types, administration route and dose, tracking of cells and documentation of therapeutic efficacy by new imaging techniques and tissue visualization. The aim of this review is to provide a summary of published studies of stem cell therapy in acute and chronic kidney injury, diabetic nephropathy, polycystic kidney disease, and kidney transplantation. Preclinical studies with allogeneic or xenogeneic cell therapy were first addressed, followed by a summary of clinical trials carried out with autologous or allogeneic hMSC. Studies were analyzed with respect to source of cell type, mechanism of action etc.

show abstract

Section: Msc Tracking and Imagingmentioning

confidence: 99%

“…- Magnetic polymeric nanoparticles to label MSC, for visualizing them by fluorescence microscopy ( 109 ).…”

Section: Msc Tracking and Imagingmentioning

confidence: 99%

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In addition, the effectiveness of BMSC transplantation for tumor intervention can be observed in real time because of the progress in modern molecular imaging. [ 7 8 ] Molecular imaging probes, owing to their molecular structures, can bind to specific targets within living cells and thus facilitate the detection of the structures and properties of the targets and generation of signals that can be monitored in real time in situ and in vivo . [ 9 ] However, real-time monitoring of biological behaviors of the tumor in vivo , such as tumor proliferation and metastatic behaviors, before and after BMSC intervention, remains difficult.…”

Section: Introductionmentioning

confidence: 99%

Magnetic Resonance Gd-RGD Imaging Study of Hepatocellular Carcinoma with High and Low Metastatic Potential before and after Human Bone Marrow-derived Mesenchymal Stem Cell Intervention

Huang³

et al. 2017

Chinese Medical Journal

View full text Add to dashboard Cite

Background:Biotherapy based on human bone marrow-derived mesenchymal stem cells (BMSCs) is currently the focus of research, especially in the field of autologous stem cell transplantation. A novel type of metastasis-associated magnetic resonance (MR) molecular imaging probe was constructed, and the changes in metastasis and proliferation of hepatocellular carcinoma (HCC) before and after BMSC intervention were observed through MR imaging (MRI).Methods:Metastasis-associated MR molecular imaging probe, integrin αvβ3 ligand cRGD-PEG-DGL-DTPA-Gd (Gd-RGD), were constructed. After human BMSC intervention was performed for 6 weeks, tumor weight inhibition rates were calculated, and the RGD molecular probe was imaged through MRI with molecular imaging agent Gd-DTPA as control. The signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) in the MRI experiment were used as semi-quantitative indicators. Polymerase chain reaction method was performed to detect proliferation- and metastasis-associated indicators, transforming growth factor β-1 (TGFβ1), osteopontin (OPN), and integrin subunit αv and β3.Results:The highest tumor weight inhibition rates were observed 3 weeks after the BMSC transplantation. The MR Gd-RGD in the HCC tissues after the BMSC intervention showed less enhancement than Gd-DTPA. The Gd-DTPA MRI of control group had higher SNR and CNR than Gd-RGD MRI in the experimental groups (P < 0.05). For high metastatic potential hepatocellular carcinoma (MHCC97-H), significant differences were observed in the SNRs and CNRs of Gd-RGD MRI before and after the BMSC intervention (P < 0.05). For low metastatic potential hepatocellular carcinoma (MHCC97-L), the CNRs of Gd-RGD MRI were statistically different before and after BMSC intervention (P < 0.05). With regard to MHCC97-H, OPN, β3, and TGFβ1 expression significantly decreased after BMSC intervention (P < 0.05). In MHCC97-L and OPN, β3, TGFβ1, and αv expression after BMSC intervention decreased, and the difference was statistically significant (P < 0.05).Conclusions:The CNR index of MRI is a good indicator for distinguishing high- and low-metastatic potential HCC tissues. After BMSC transplantation of MRI through the two kinds of tracer, the SNR and CNR indexes can distinguish two kinds of high and low metastatic potential HCC tissues, and Gd-RGD imaging is more suitable in distinguishing the metastatic potential changes through BMSC intervention.

show abstract

“…Altogether, these results indicated that FITC@NPs coated with silica or CMCh are a valuable tool to investigate the interactions of NPs both in in vitro cell culture and in vivo. [238] Following studies aimed to label rMSCs using magnetic FITC@ChNPs, generated by Kaewsaneha et al [239,240] After incubation of rMSC with NPs, the labeling efficiency was timedependent, achieving the highest fluorescence after 24 h incubation with no impacts on cell viability. Labeled cells were then 3D imaged to check the location of NPs which were mainly detected in the cytoplasm, suggesting endocytosis as the uptake mechanism.…”

Section: Cellular Labelingmentioning

confidence: 99%

“…These results classify magnetic FITC@ChNPs as a powerful potential tool for rMSC labeling, allowing cell tracking and visualization by fluorimetry. [239] Kaewsaneha et al [241] used a method developed by Kaewsaneha et al, [240] incorporating iron oxide into polystyrene/ divinyl benzene/acrylic acid by miniemulsion polymerization while FITC was immobilized using chitosan as a spacer. The MW of chitosan employed in this method was high enough (300 kDa) to avoid direct contact between the iron core and FITC, so that quenching was prevented.…”

Section: Cellular Labelingmentioning

confidence: 99%

Biomedical and Pharmacological Uses of Fluorescein Isothiocyanate Chitosan‐Based Nanocarriers

Caprifico

Polycarpou

Foot

et al. 2020

Macromolecular Bioscience

View full text Add to dashboard Cite

with a DDA ranging between 70% and 85% becomes soluble in dilute acidic solutions such as acetic acid or formic acid. [1] Indeed, the primary amino groups of chitosan have a pK a of ≈6.5 so that, following protonation, they confer upon chitosan the feature of solubility in weakly acidic aqueous solution, allowing the polymer to be easily manipulated. [3] The DDA of chitosan plays a key role in determining its physicochemical properties, which are affected by the proportion of free amino groups (-NH 2) remaining on the polymeric chain upon deacetylation. Both the primary amino and secondary hydroxyl groups behave as reactive functional groups on chitosan. Indeed, these groups allow chitosan to be susceptible to chemical modifications such as acylation, tosylation, quaternization, alkylation, and O-carboxymethylation. [4] As a result, the chitosan structure can be functionalized and optimized to improve drug loading or release. [5] Chitosan-based nanocarriers (ChNCs), including nanoparticles (NPs), micelles, or polyplexes, have received significant attention for their numerous advantageous features such as natural sourcing, biodegradability, easy functionalizations, and low toxicity. [6] The mucoadhesive property of chitosan is key for drug delivery purposes. [7] Indeed, chitosan is a positively charged polymer that can form electrostatic bonds with the negatively charged mucous layer, made of mucin glycoproteins that cover the epithelial cells of the mucosa. The establishment of these bonds allows drug-loaded ChNCs to exhibit higher absorption and retention times at the target, while reducing dosing frequency. [8] Furthermore, chitosan is used as permeation enhancer since increases the uptake of the drugs through a transient and reversible opening of the tight junctions (TJs) protecting the paracellular pathway between endothelial cells in the so-called blood-brain barrier (BBB). [9] This is due to F-actin depolymerization and leakage of the TJ protein zonula occludens-1. [7] The small size and large surface area of NCs allow their passage through biological membranes, such the BBB, and accumulation at the intracellular (such as lysosomes) or intranuclear (DNA or RNA) target site. [10] ChNCs are distinctive for their ability to protect the encapsulated therapeutic agent and improve its bioavailability by altering the pharmacokinetics. [10] The endocytic mechanisms responsible for the internalization of ChNCs as a drug delivery system may differ according to the cell type and the drug to be delivered. Numerous biological and pharmacological properties characterize chitosan. These include antitumor, antifungal, antioxidant, immunoenhancing, and wound healing properties. [11] Furthermore, chitosan is Chitosan-based nanocarriers (ChNCs) are considered suitable drug carriers due to their ability to encapsulate a variety of drugs and cross biological barriers to deliver the cargo to their target site. Fluorescein isothiocyanatelabeled chitosan-based NCs (FITC@ChNCs) are used extensively in biomedical and pharmacological...

show abstract

Mesenchymal stem cell in vitro labeling by hybrid fluorescent magnetic polymeric particles for application in cell tracking

Cited by 7 publications

References 48 publications

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

Magnetic Resonance Gd-RGD Imaging Study of Hepatocellular Carcinoma with High and Low Metastatic Potential before and after Human Bone Marrow-derived Mesenchymal Stem Cell Intervention

Biomedical and Pharmacological Uses of Fluorescein Isothiocyanate Chitosan‐Based Nanocarriers

Contact Info

Product

Resources

About